When a health company builds its team in a new country, it almost always hires sales and marketing first and leaves Medical Affairs for after launch. That's an expensive mistake. In health, the decision to adopt a technology is made by a clinician who trusts the evidence — and that trust is built by neither a salesperson nor a campaign.
What Medical Affairs is not
It is not sales and it is not marketing. That distinction isn't about the org chart: it's regulatory and ethical. Scientific interaction with a clinician has to be separated from the commercial incentive, or it loses all credibility. Blurring the functions is the fastest way to burn the relationship with the clinical community.
| Function | Goal | Counterpart | Measured by |
|---|---|---|---|
| Sales | Close the purchase | Buyer / institution | Revenue |
| Marketing | Position the brand | The market | Demand generated |
| Medical Affairs | Education and scientific exchange | Clinician and opinion leader | Evidence and clinical trust |
The MSL: the role almost no one understands from outside
The heart of Medical Affairs is the medical science liaison, or MSL. It's a clinical or scientific profile — not a commercial one — whose job is to sustain a peer-to-peer dialogue with opinion leaders: the clinicians who define how a condition is treated in a hospital, a medical society, or a region.
The MSL doesn't ask for a sale. They carry evidence both ways: explaining the data, listening to the real questions of local clinical practice, spotting which questions your study doesn't yet answer, and bringing that back to the company. In LatAm, where clinical practice and resources vary enormously between countries, that listening loop is worth as much as the information it delivers.
Evidence and education are the product
Medical Affairs works with publications, practice guidelines, advisory boards of local experts, medical information responses, and education programs. None of that is promotion: it's the credibility infrastructure that means, when sales finally arrives, the clinician already knows and trusts the data.
Warning signIf your only voice in front of the medical community is a commercial one, you don't have a sales problem: you have a credibility problem, and more salespeople won't fix it.
Why it's the bridge
Medical Affairs is the one function that touches every other link in access. It feeds the regulatory team the clinical read, helps HEOR define which outcomes matter to the payer, and gives the commercial side a foundation of trust to sell on. When it's missing, each area improvises its own version of the science — and the market notices.
When to build it
Before launch, not after. Clinical trust is built over time and with consistent presence; showing up to ask for it the day you need to sell is showing up late. It's also the function that connects to health economics — the value argument (HEOR) — and to the regulatory and market-access strategy we cover across the rest of this series.